Robot-assisted urological tumor surgery using the MP1000 system: A prospective, single-center, single-arm clinical...

This study is aimed to evaluate the safety and efficacy of the MP1000 robotic system in urological tumor surgery.

This prospective, single-center, single-arm clinical study evaluated data from urological tumor surgeries between June 2023 and December 2023. Patient demographics and perioperative outcomes were prospectively collected, and postoperative complications and success rates were analyzed. Ergonomics were assessed using the National Aeronautics and Space Administration Task Load Index.

A total of 28 patients underwent surgery during the study period. All procedures were successfully completed without conversion to standard laparoscopic or open surgery. All cases had negative surgical margins postoperatively, and no recurrences were observed within 3 months. The median glomerular filtration rate (GFR) at the third month after partial nephrectomy was 87.4 mL/min/1.73 m² (range, 55.64-124.33 mL/min/1.73 m²). The median GFR at the third month after nephroureterectomy was 65.52 mL/min/1.73 m² (range, 65.52-98.12 mL/min/1.73 m²). The GFR at the third month after radical nephrectomy was 57.22 mL/min/1.73 m². The median prostate-specific antigen level for patients after radical prostatectomy was 0.01 ng/mL (range, 0-0.03 ng/mL) at 3 months. The short-term surgical success rate was 100%. Surgeons reported high comfort levels, with an overall National Aeronautics and Space Administration Task Load Index score of 12.89 ± 7.14.

Based on our single-center experience, the MP1000 system demonstrated promising safety and efficacy in a variety of urological tumor surgeries.